Platelet Factor Four and Protamine Sulfate Neutralization of Heparin Fractionated According to Anionic Charge Density

Man-Chiu Poon; Robert E Hurst; Michael S Rives

doi:10.1055/s-0038-1657154

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1982; 47(02): 162-165
DOI: 10.1055/s-0038-1657154

Original Article

Schattauer GmbH Stuttgart

Platelet Factor Four and Protamine Sulfate Neutralization of Heparin Fractionated According to Anionic Charge Density

Authors

Man-Chiu Poon

¹University of Alabama in Birmingham, and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, U.S.A.
Robert E Hurst

²The Division of Hematology and Oncology, Department of Medicine and the School of Public Health and Department of Biochemistry, Birmingham, Alabama, U.S.A.
Michael S Rives

¹University of Alabama in Birmingham, and the Birmingham Veterans Administration Medical Center, Birmingham, Alabama, U.S.A.

Abstract

PDF Download

Summary

The role of heparin structure in neutralization by the neutralizing substances (NS) platelet factor 4 (PF4) and protamine sulfate (PS) was investigated using a thrombin clotting assay and a series of more homogeneous heparin fractions varying systematically in charge density (Z). For a given heparin, plotting inverse clotting times measured without NS, and in the presence of PF4 or PS, vs heparin concentration yielded approximately parallel straight lines displaced horizontally according to the amount of NS. Potencies of heparin fractions in the absence of NS, or in the presence of PF4 or PS, depended almost identically upon Z². Small but significant quantitative differences in potency among equivalent fractions from different heparins showed both PF4 and PS had a slight preference for the least active subfraction of decolorized heparins, but for the most active subfraction of undecolorized heparins. Neutralization of heparin by PF4 and PS probably proceeds by similar mechanisms, but the details of structure outside the antithrombin III-binding oligosaccharide of heparin may enter in differently.

Key words

Heparin - Anionic density - Platelet factor 4 (PF4) - Protamine sulfate - Heparin neutralization

PDF (841 kb)

References

References
1 Poplawski A, Niewiarowski S. Method for determining antiheparin activity of platelets and erythrocytes. Thrombos Diathes Haemorrh 1965; 13: 149-154
2 Moore S, Pepper DS, Cash JD. Platelet antiheparin activity. The isolation and characterization of platelet factor 4 released from thrombin-aggregated washed human platelets and its dissociation into subunits and the isolation of membrane-bound antiheparin activity. Biochim Biophys Acta 1975; 379: 370-384
3 Niewiarowski S, Rucinski B, James P, Lindahl U. Platelet antiheparin proteins and antithrombin III interaction with different binding sites on heparin molecules. FEBS Lett 1979; 102: 75-78
4 Michalski R, Lane DA, Pepper DS, Kakkar VV. Neutralization of heparin in plasma by platelet factor 4 and protamine sulfate. Br J Haematol 1978; 38: 561-573
5 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
6 Höök M, Björk I, Hopwood J, Lindahl U. Anticoagulant activities of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976; 66: 90-93
7 Hurst RE, Menter JM, West SS, Settine JM, Coyne EH. Structural basis for the anticoagulant activity of heparin I. Relationship to the number of charged groups. Biochemistry 1979; 18: 4238-4287
8 Hurst RE, van Dedem G, Settine JM. Biophysical characteristics of anionic density-fractionated mucosal heparins in relation to potencies in anticoagulant and thrombin-inhibition assays. Thromb Res 1981; 22: 663-643
9 Menter JM, Hurst RE, Nakamura N, West SS. Thermodynamics of mucopolysaccharide-dye binding III. Thermodynamic and cooperativity parameters of acridine orange – heparin system. Biopolymers 1979; 18: 493-505
10 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol. Chem 1976; 251: 4273-4282
11 Biggs R. Human Blood Coagulation. Haemostasis and Thrombosis. 713-715 Blackwell, Oxford: 1976
12 Forman WB, Ratnoff OD, Boyer MH. An inherited abnormality in plasma fibrinogen: fibrinogen Cleveland. J Lab Clin Med 1968; 72: 455-472
13 Saito H, Ratnoff OD, Waldman R, Abraham JP. Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reaction of clotting, fibrinolysis, generation of kinin, and the property of diluted plasma enhancing vascular permeability (PF/dil). J Clin Invest 1975; 55: 1082-1089
14 Levine SD, Whol H. Human platelet factor 4. Purification and characterization by affinity chromatography. J Biol Chem 1976; 251: 324-328
15 Lundblad RL. Rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme with phenylmethylsulfonyl fluoride. Biochemistry 1971; 10: 2501-2505
16 Prentice CRM, Ratnoff OD, Breckenridge RT. Experiments on the nature of the prothrombin-converting principle: alteration of proaccelerin by thrombin. Br J Haematol 1967; 13: 898-914
17 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
18 Coyne E. Heparin – past, present and future. In: Chemistry and Biology of Heparin. Lundblad RL, Brown WV, Mann KG, Roberts HR. (eds.) 9-17 New York, Elsevier/North Holland: 1981